logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On November 4th, PRU (02378) spent 3.0024 million to repurchase 281,500 shares.

date
16:54 05/11/2025
avatar
GMT Eight
Baocheng (02378) announced that the company will repurchase... at a cost of 3.24 million pounds on November 4, 2025.
PRU (02378) announced that on November 4, 2025, the company spent 3.0024 million pounds to repurchase 28.15 million shares, with a repurchase price of 10.44-10.745 pounds per share.
Related Articles
HK Stock
WINTO GROUP (08238): Placing Agreement lapses
Fidelity International increased its holdings of CH OVS G OCEANS (00081) by 4.4 million shares at an average price of approximately 2.18 Hong Kong dollars per share.
China Stock
Subsidiary of Shandong Jincheng Pharmaceutical Group (300233.SZ) plans to sell a drug production technology and the rights of the holder of the marketing license to Haemoni.
WINTO GROUP (08238): Placing Agreement lapses
HK Stock
Fidelity International increased its holdings of CH OVS G OCEANS (00081) by 4.4 million shares at an average price of approximately 2.18 Hong Kong dollars per share.
Subsidiary of Shandong Jincheng Pharmaceutical Group (300233.SZ) plans to sell a drug production technology and the rights of the holder of the marketing license to Haemoni.
China Stock
RECOMMEND
Starbucks China Transaction: Aggressive Expansion, the South Korea Precedent, and Persistent Core Challenges
Starbucks China Transaction: Aggressive Expansion, the South Korea Precedent, and Persistent Core Challenges
icon
05/11/2025
Supor’s Slowdown: Profit Plunge, Executive Share Sales, and Challenges Under Foreign Control
Supor’s Slowdown: Profit Plunge, Executive Share Sales, and Challenges Under Foreign Control
icon
05/11/2025
Central Bank Resumes Bond Trading and Launches ¥700 Billion Outright Reverse Repo
Central Bank Resumes Bond Trading and Launches ¥700 Billion Outright Reverse Repo
icon
05/11/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.